PMID- 26992208
OWN - NLM
STAT- MEDLINE
DCOM- 20180223
LR  - 20181113
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 17
DP  - 2016 Apr 26
TI  - Distinct effects of SIRT1 in cancer and stromal cells on tumor promotion.
PG  - 23975-87
LID - 10.18632/oncotarget.8073 [doi]
AB  - The lysyl deacetylase SIRT1 acts as a metabolic sensor in adjusting metabolic 
      imbalance. To explore the role of SIRT1 in tumor-stroma interplay, we designed an 
      in vivo tumor model using SIRT1-transgenic mice. B16F10 mouse melanoma grew more 
      quickly in SIRT1-transgenic mice than in wild-type mice, whereas 
      SIRT1-overexpressing one grew slowly in both mice. Of human tumors, SIRT1 
      expression in stromal fibroblasts was found to correlate with poor prognosis in 
      ovarian cancer. B16F10 and human ovarian cancer (SKOV3 and SNU840) cells were 
      more proliferative in co-culture with SIRT1-overexpressiong fibroblasts. In 
      contrast, SIRT1 within cancer cells has a negative effect on cell proliferation. 
      In conditioned media from SIRT1-overexpressing fibroblasts, matrix 
      metalloproteinase-3 (MMP3) was identified in cytokine arrays to be secreted from 
      fibroblasts SIRT1-dependently. Fibroblast-derived MMP3 stimulated cancer cell 
      proliferation, and such a role of MMP3 was also demonstrated in cancer/fibroblast 
      co-grafts. In conclusion, SIRT1 plays differential roles in cancer and stromal 
      cells. SIRT1 in stromal cells promotes cancer growth by producing MMP3, whereas 
      SIRT1 in cancer cells inhibits growth via an intracellular event. The present 
      study provides a basis for setting new anticancer strategies targeting SIRT1.
FAU - Shin, Dong Hoon
AU  - Shin DH
AD  - Department of Pharmacology, Seoul National University College of Medicine, Seoul 
      110-799, Republic of Korea.
AD  - Lung Cancer Branch, Division of Translational & Clinical Research, Department of 
      System Cancer Science, Graduate School of Cancer Science and Policy, National 
      Cancer Center, Gyeonggi-do 410-769, Republic of Korea.
FAU - Choi, Yong-Joon
AU  - Choi YJ
AD  - Department of Biomedical Sciences, Seoul National University College of Medicine, 
      Seoul 110-799, Republic of Korea.
FAU - Jin, Peng
AU  - Jin P
AD  - Department of Biomedical Sciences, Seoul National University College of Medicine, 
      Seoul 110-799, Republic of Korea.
FAU - Yoon, Haejin
AU  - Yoon H
AD  - Department of Biomedical Sciences, Seoul National University College of Medicine, 
      Seoul 110-799, Republic of Korea.
FAU - Chun, Yang-Sook
AU  - Chun YS
AD  - Department of Biomedical Sciences, Seoul National University College of Medicine, 
      Seoul 110-799, Republic of Korea.
AD  - Ischemic/Hypoxic Disease Institute and Cancer Research Institute, Seoul National 
      University College of Medicine, Seoul 110-799, Republic of Korea.
FAU - Shin, Hyun-Woo
AU  - Shin HW
AD  - Department of Pharmacology, Seoul National University College of Medicine, Seoul 
      110-799, Republic of Korea.
AD  - Department of Biomedical Sciences, Seoul National University College of Medicine, 
      Seoul 110-799, Republic of Korea.
AD  - Ischemic/Hypoxic Disease Institute and Cancer Research Institute, Seoul National 
      University College of Medicine, Seoul 110-799, Republic of Korea.
FAU - Kim, Ja-Eun
AU  - Kim JE
AD  - Department of Pharmacology, School of Medicine, Kyung Hee University, Seoul 
      02447, Republic of Korea.
FAU - Park, Jong-Wan
AU  - Park JW
AD  - Department of Pharmacology, Seoul National University College of Medicine, Seoul 
      110-799, Republic of Korea.
AD  - Department of Biomedical Sciences, Seoul National University College of Medicine, 
      Seoul 110-799, Republic of Korea.
AD  - Ischemic/Hypoxic Disease Institute and Cancer Research Institute, Seoul National 
      University College of Medicine, Seoul 110-799, Republic of Korea.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Culture Media, Conditioned)
RN  - EC 3.5.1.- (SIRT1 protein, human)
RN  - EC 3.5.1.- (Sirtuin 1)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - Biomarkers, Tumor/*metabolism
MH  - Cell Communication
MH  - Cell Proliferation
MH  - Cell Transformation, Neoplastic/metabolism/*pathology
MH  - Coculture Techniques
MH  - Culture Media, Conditioned
MH  - Female
MH  - Fibroblasts/metabolism/*pathology
MH  - Humans
MH  - Melanoma, Experimental/metabolism/*pathology
MH  - Mice
MH  - Mice, Nude
MH  - Mice, Transgenic
MH  - Ovarian Neoplasms/metabolism/*pathology
MH  - Sirtuin 1/*metabolism
MH  - Stromal Cells/metabolism/*pathology
MH  - Tumor Cells, Cultured
MH  - Xenograft Model Antitumor Assays
PMC - PMC5029678
OTO - NOTNLM
OT  - MMP3
OT  - SIRT1
OT  - stroma
OT  - tumor
COIS- All authors have no conflict of interest to declare.
EDAT- 2016/03/19 06:00
MHDA- 2018/02/24 06:00
PMCR- 2016/04/26
CRDT- 2016/03/19 06:00
PHST- 2015/11/14 00:00 [received]
PHST- 2016/02/28 00:00 [accepted]
PHST- 2016/03/19 06:00 [entrez]
PHST- 2016/03/19 06:00 [pubmed]
PHST- 2018/02/24 06:00 [medline]
PHST- 2016/04/26 00:00 [pmc-release]
AID - 8073 [pii]
AID - 10.18632/oncotarget.8073 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Apr 26;7(17):23975-87. doi: 10.18632/oncotarget.8073.